source
- Trump's Department of War bets $47M on Flagship biotechs to develop countermeasuresThe Department of War has awarded Flagship Pioneering $47 million to develop medical countermeasure technologies against emerging threats.
- Roche’s dual GLP-1/GIP drug enicepatide lowers HbA1c in phase 2 trial, sparking best-in-disease hopesRoche reported that its dual GLP-1/GIP receptor agonist, enicepatide, met the primary goals of a phase 2 study in patients with type 2 diabetes. The top 24‑mg weekly dose reduced HbA1c by 2.65% ove…